Adaptive Historical Income Statement

ADPT Stock

USD 6.39 0.07 1.11%

Historical analysis of Adaptive Biotechnologies income statement accounts such as Discontinued Operations of 0.0, Depreciation And Amortization of 13.1 M or Interest Expense of 14.5 M can show how well Adaptive Biotechnologies Corp performed in making a profits. Evaluating Adaptive Biotechnologies income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Adaptive Biotechnologies's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Adaptive Biotechnologies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Adaptive Biotechnologies is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

About Adaptive Income Statement Analysis

Adaptive Biotechnologies Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Adaptive Biotechnologies shareholders. The income statement also shows Adaptive investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Adaptive Biotechnologies Income Statement Chart

At this time, Adaptive Biotechnologies' Interest Income is comparatively stable compared to the past year. Interest Expense is likely to gain to about 14.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 57.1 M in 2024.

Selling General Administrative Selling And Marketing Expenses Total Revenue Gross Profit

Total Revenue

Total revenue comprises all receipts Adaptive Biotechnologies generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Adaptive Biotechnologies Corp minus its cost of goods sold. It is profit before Adaptive Biotechnologies operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from Adaptive Biotechnologies' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Adaptive Biotechnologies current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

	2021	2022	2023	2024 (projected)
Gross Profit	105.0M	127.4M	94.7M	82.4M
Total Revenue	154.3M	185.3M	170.3M	123.7M

Gross Profit Total Revenue

Adaptive Biotechnologies income statement Correlations

	Net Interest Income	Interest Income	Depreciation And Amortization	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Non Operating Income Net Other
Net Interest Income		0.04	-0.34	-0.25	-0.18	-0.2	-0.09	-0.21	0.26	0.27	0.23	-0.08	0.21	-0.4	-0.17	-0.39	0.29	0.79	0.3	0.07	0.43
Interest Income	0.04		0.46	0.56	0.55	0.59	0.56	0.59	-0.67	-0.62	-0.67	0.55	-0.68	0.61	0.58	0.59	-0.66	0.58	-0.69	-0.03	-0.43
Depreciation And Amortization	-0.34	0.46		0.99	0.97	0.97	0.95	0.98	-0.94	-0.95	-0.93	0.95	-0.92	0.92	0.97	0.95	-0.95	0.13	-0.88	-0.59	-0.84
Selling General Administrative	-0.25	0.56	0.99		0.99	0.99	0.98	1.0	-0.97	-0.96	-0.95	0.97	-0.95	0.95	0.99	0.96	-0.97	0.26	-0.91	-0.54	-0.85
Selling And Marketing Expenses	-0.18	0.55	0.97	0.99		0.99	0.98	1.0	-0.97	-0.97	-0.97	0.99	-0.96	0.91	1.0	0.92	-0.97	0.32	-0.92	-0.5	-0.87
Total Revenue	-0.2	0.59	0.97	0.99	0.99		0.99	0.99	-0.96	-0.95	-0.95	0.97	-0.94	0.94	0.99	0.96	-0.96	0.31	-0.9	-0.56	-0.85
Gross Profit	-0.09	0.56	0.95	0.98	0.98	0.99		0.97	-0.94	-0.95	-0.94	0.98	-0.94	0.87	0.98	0.9	-0.94	0.39	-0.87	-0.61	-0.82
Other Operating Expenses	-0.21	0.59	0.98	1.0	1.0	0.99	0.97		-0.97	-0.97	-0.97	0.98	-0.96	0.94	1.0	0.94	-0.97	0.31	-0.93	-0.49	-0.86
Operating Income	0.26	-0.67	-0.94	-0.97	-0.97	-0.96	-0.94	-0.97		1.0	1.0	-0.96	1.0	-0.91	-0.97	-0.9	1.0	-0.3	0.98	0.38	0.89
Net Income From Continuing Ops	0.27	-0.62	-0.95	-0.96	-0.97	-0.95	-0.95	-0.97	1.0		1.0	-0.97	0.99	-0.89	-0.97	-0.89	1.0	-0.28	0.97	0.42	0.9
Ebit	0.23	-0.67	-0.93	-0.95	-0.97	-0.95	-0.94	-0.97	1.0	1.0		-0.96	1.0	-0.88	-0.97	-0.88	1.0	-0.33	0.98	0.37	0.89
Research Development	-0.08	0.55	0.95	0.97	0.99	0.97	0.98	0.98	-0.96	-0.97	-0.96		-0.96	0.85	0.99	0.86	-0.95	0.4	-0.91	-0.5	-0.82
Ebitda	0.21	-0.68	-0.92	-0.95	-0.96	-0.94	-0.94	-0.96	1.0	0.99	1.0	-0.96		-0.87	-0.97	-0.86	0.99	-0.35	0.98	0.35	0.88
Cost Of Revenue	-0.4	0.61	0.92	0.95	0.91	0.94	0.87	0.94	-0.91	-0.89	-0.88	0.85	-0.87		0.92	0.99	-0.91	0.14	-0.88	-0.42	-0.84
Total Operating Expenses	-0.17	0.58	0.97	0.99	1.0	0.99	0.98	1.0	-0.97	-0.97	-0.97	0.99	-0.97	0.92		0.93	-0.97	0.33	-0.93	-0.49	-0.85
Reconciled Depreciation	-0.39	0.59	0.95	0.96	0.92	0.96	0.9	0.94	-0.9	-0.89	-0.88	0.86	-0.86	0.99	0.93		-0.91	0.12	-0.85	-0.55	-0.8
Income Before Tax	0.29	-0.66	-0.95	-0.97	-0.97	-0.96	-0.94	-0.97	1.0	1.0	1.0	-0.95	0.99	-0.91	-0.97	-0.91		-0.27	0.98	0.38	0.89
Total Other Income Expense Net	0.79	0.58	0.13	0.26	0.32	0.31	0.39	0.31	-0.3	-0.28	-0.33	0.4	-0.35	0.14	0.33	0.12	-0.27		-0.28	-0.02	-0.06
Net Income	0.3	-0.69	-0.88	-0.91	-0.92	-0.9	-0.87	-0.93	0.98	0.97	0.98	-0.91	0.98	-0.88	-0.93	-0.85	0.98	-0.28		0.2	0.9
Income Tax Expense	0.07	-0.03	-0.59	-0.54	-0.5	-0.56	-0.61	-0.49	0.38	0.42	0.37	-0.5	0.35	-0.42	-0.49	-0.55	0.38	-0.02	0.2		0.24
Non Operating Income Net Other	0.43	-0.43	-0.84	-0.85	-0.87	-0.85	-0.82	-0.86	0.89	0.9	0.89	-0.82	0.88	-0.84	-0.85	-0.8	0.89	-0.06	0.9	0.24

Click cells to compare fundamentals

Adaptive Biotechnologies Account Relationship Matchups

Adaptive Biotechnologies income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Net Interest Income	9.8M	6.6M	1.7M	(182K)	(853K)	(810.4K)
Interest Income	9.8M	6.6M	1.7M	4.1M	13.5M	14.2M
Depreciation And Amortization	171.9K	11.7M	21.0M	28.1M	22.2M	13.1M
Selling General Administrative	30.3M	49.5M	74.5M	88.5M	83.9M	57.1M
Selling And Marketing Expenses	38.5M	61.4M	95.5M	95.6M	88.6M	66.1M
Total Revenue	85.1M	98.4M	154.3M	185.3M	170.3M	123.7M
Gross Profit	62.8M	75.9M	105.0M	127.4M	94.7M	82.4M
Other Operating Expenses	163.5M	251.2M	363.3M	385.5M	397.3M	274.7M
Operating Income	(78.4M)	(152.8M)	(209.0M)	(200.2M)	(227.0M)	(215.7M)
Net Income From Continuing Ops	(68.6M)	(146.2M)	(207.3M)	(200.4M)	(196.0M)	(205.8M)
Ebit	(76.9M)	(156.1M)	(214.3M)	(196.1M)	(211.5M)	(222.1M)
Research Development	70.7M	116.1M	142.3M	141.8M	122.1M	104.4M
Ebitda	(76.7M)	(144.3M)	(193.3M)	(168.0M)	(189.3M)	(198.7M)
Cost Of Revenue	22.3M	22.5M	49.3M	57.9M	75.6M	41.3M
Total Operating Expenses	141.2M	228.7M	314.0M	327.6M	321.8M	233.4M
Reconciled Depreciation	7.8M	8.5M	14.0M	20.9M	22.1M	13.4M
Income Before Tax	(68.6M)	(146.2M)	(207.3M)	(200.4M)	(225.3M)	(214.0M)
Total Other Income Expense Net	9.8M	6.6M	1.7M	(182K)	1.7M	2.5M
Net Income Applicable To Common Shares	(69.6M)	(146.2M)	(207.3M)	(200.2M)	(180.2M)	(189.2M)
Net Income	(58.8M)	(139.6M)	(205.6M)	(142.5M)	(225.3M)	(214.0M)
Income Tax Expense	(9.8M)	(6.6M)	(1.7M)	(57.9M)	(54K)	(56.7K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adaptive Historical Income Statement

About Adaptive Income Statement Analysis

Adaptive Biotechnologies Income Statement Chart

Total Revenue

Gross Profit

Adaptive Biotechnologies income statement Correlations

Adaptive Biotechnologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adaptive Biotechnologies income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Adaptive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Interest Income	Interest Income
Discontinued Operations	Depreciation And Amortization
Interest Expense	Selling General Administrative
Selling And Marketing Expenses	Total Revenue
Gross Profit	Other Operating Expenses
Operating Income	Net Income From Continuing Ops
Ebit	Research Development
Ebitda	Cost Of Revenue
Non Recurring	Total Operating Expenses
Reconciled Depreciation	Effect Of Accounting Charges
Income Before Tax	Extraordinary Items
Total Other Income Expense Net	Net Income Applicable To Common Shares
Net Income	Income Tax Expense
Minority Interest	Other Items
Tax Provision	Non Operating Income Net Other

Other Operating Expenses	+ 1.0	Selling General Administrative
Other Operating Expenses	+ 1.0	Selling And Marketing Expenses
Total Operating Expenses	+ 1.0	Selling And Marketing Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income

Income Before Tax	- 0.97	Total Operating Expenses
Total Operating Expenses	- 0.97	Ebitda
Total Operating Expenses	- 0.97	Ebit
Total Operating Expenses	- 0.97	Net Income From Continuing Ops
Research Development	- 0.97	Net Income From Continuing Ops
Total Operating Expenses	- 0.97	Operating Income